25.41

4.35% 1.06

After Hours: 25.41

Enliven Therapeutics Inc (ELVN)

Overview News Price History Option Chain Financials Discussions Forecast

Enliven Therapeutics Inc stock is traded at $25.41, with a volume of 165.83K. It is up +4.35% in the last 24 hours and down -11.80% over the past month. Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.

Previous Close:

$24.35

Open:

$24.45

24h Volume:

165.83K

Relative Volume:

0.66

Market Cap:

$1.21B

Revenue:

Net Income/Loss:

$-82.83M

P/E Ratio:

-20.47

EPS:

-1.2413

Net Cash Flow:

$-72.22M

1W Performance:

-0.08%

1M Performance:

-11.80%

6M Performance:

+6.14%

1Y Performance:

+131.00%

1-Day Range:

$24.45

$25.67

1-Week Range:

$24.10

$26.09

52-Week Range:

$9.80

$30.03

Enliven Therapeutics Inc Stock (ELVN) Company Profile

Name

Enliven Therapeutics Inc

Sector

Healthcare (1200)

Industry

Biotechnology (682)

Phone

720-647-8519

Address

6200 LOOKOUT ROAD, BOULDER

Employee

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

ELVN's Discussions on Twitter

Compare ELVN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ELVN Enliven Therapeutics Inc	25.41	1.21B	0	-82.83M	-72.22M	-1.2413
VRTX Vertex Pharmaceuticals Inc	464.56	119.70B	10.63B	-479.80M	-1.35B	13.33
REGN Regeneron Pharmaceuticals Inc	754.87	82.75B	13.85B	4.65B	3.32B	35.06
ARGX Argen X Se Adr	614.59	36.73B	1.86B	-40.29M	-1.28B	-4.16
ALNY Alnylam Pharmaceuticals Inc	253.74	32.53B	2.09B	-332.26M	16.06M	-4.14
BNTX Biontech Se Adr	120.72	28.50B	3.30B	-501.07M	1.03B	11.54

Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-09-24	Initiated	H.C. Wainwright	Buy
Jun-11-24	Initiated	Robert W. Baird	Outperform
Apr-09-24	Initiated	Mizuho	Buy
Mar-29-23	Initiated	Jefferies	Buy

Enliven Therapeutics Inc Stock (ELVN) Latest News

Nov 25, 2024

Enliven Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 - Marketscreener.com

Nov 25, 2024

Nov 22, 2024

(ELVN) Investment Analysis - Stock Traders Daily

Nov 22, 2024

Nov 21, 2024

Enliven Therapeutics to Present at the Jefferies London Healthca - GuruFocus.com

Nov 21, 2024

Nov 19, 2024

Short Interest in Enliven Therapeutics, Inc. (NASDAQ:ELVN) Increases By 6.1% - MarketBeat

Nov 19, 2024

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Bought by First Turn Management LLC - MarketBeat

Nov 19, 2024

Robert W. Baird Issues Positive Forecast for Enliven Therapeutics (NASDAQ:ELVN) Stock Price - Defense World

Nov 19, 2024

Nov 16, 2024

Enliven Therapeutics has cash runway into late 2026 - BizWest

Nov 16, 2024

Nov 15, 2024

Robert W. Baird Forecasts Strong Price Appreciation for Enliven Therapeutics (NASDAQ:ELVN) Stock - MarketBeat

Nov 15, 2024

RA Capital Management, L.P. Reduces Stake in Enliven Therapeutics Inc. - GuruFocus.com

Nov 15, 2024

Polar Capital Holdings Plc's Strategic Acquisition in Enliven Th - GuruFocus.com

Nov 13, 2024

Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update - PR Newswire

Nov 13, 2024

Nov 11, 2024

(ELVN) Investment Analysis and Advice - Stock Traders Daily

Nov 11, 2024

Nov 07, 2024

Enliven Therapeutics to Present at the Jefferies London Healthcare Conference - StockTitan

Nov 07, 2024

Nov 01, 2024

How to Take Advantage of moves in (ELVN) - Stock Traders Daily

Nov 01, 2024

Oct 31, 2024

Jones Trading Initiates Coverage of Enliven Therapeutics (ELVN) with Buy Recommendation - MSN

Oct 31, 2024

This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga

Oct 31, 2024

Enliven Therapeutics CFO Benjamin Hohl sells shares worth $178,484 By Investing.com - Investing.com South Africa

Oct 31, 2024

Oct 30, 2024

Enliven Therapeutics CFO Benjamin Hohl sells shares worth $178,484 - Investing.com

Oct 30, 2024

Oct 27, 2024

Enliven Therapeutics (ELVN) Price Target Increased by 10.75% to 35.02 - MSN

Oct 27, 2024

Oct 23, 2024

Enliven Therapeutics CFO sells $24,422 in stock By Investing.com - Investing.com Australia

Oct 23, 2024

Oct 22, 2024

Enliven Therapeutics CFO sells $24,422 in stock - Investing.com

Oct 22, 2024

Enliven Therapeutics chief medical officer sells $24,482 in stock By Investing.com - Investing.com Canada

Oct 22, 2024

Enliven Therapeutics chief medical officer sells $24,482 in stock - Investing.com India

Oct 22, 2024

Enliven Therapeutics COO Anish Patel sells $21,482 in stock - Investing.com

Oct 22, 2024

Enliven Therapeutics COO Anish Patel sells $21,482 in stock By Investing.com - Investing.com Australia

Oct 22, 2024

Enliven Therapeutics' chief scientific officer sells $25,412 in stock By Investing.com - Investing.com Australia

Oct 22, 2024

Enliven Therapeutics CEO Kintz sells $27,722 in stock - Investing.com

Oct 22, 2024

Enliven Therapeutics' chief scientific officer sells $25,412 in stock - Investing.com India

Oct 22, 2024

Enliven Therapeutics director Heyman sells $47,104 in stock By Investing.com - Investing.com Australia

Oct 22, 2024

Enliven Therapeutics CEO Kintz sells $27,722 in stock By Investing.com - Investing.com Australia

Oct 22, 2024

Enliven Therapeutics director Heyman sells $47,104 in stock - Investing.com India

Oct 22, 2024

Anish Patel Sells 716 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock - MarketBeat

Oct 22, 2024

Oct 21, 2024

When (ELVN) Moves Investors should Listen - Stock Traders Daily

Oct 21, 2024